A Phase 3 interventional study of JKN2301 Dry Suspension and Oseltamivir Placebo in Respiratory Viral Infection, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Recruiting at 1 site in China. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.
Joincare Pharmaceutical Group Industry Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: JKN2301 Dry Suspension · Drug: Oseltamivir Placebo
Drug: Oseltamivir · Drug: JKN2301 Placebo
Single oral dose, administered according to a weight-tiered dosing scheme.
Oral suspension, administered twice daily for 5 days, matched to the weight-based dosing of active oseltamivir.
Oral suspension, administered twice daily for 5 days according to the approved weight-based dosing regimen.
Single oral dose, matched to the weight-tiered dosing scheme of active JKN2301.
Incidence, severity, and relationship to treatment of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Baseline through Day 15
Clinically significant changes in laboratory parameters, vital signs, physical examination, and ECG
Time frame: Baseline through Day 15
Plasma concentration-time profiles of JKN2301 and its relevant metabolites
Time frame: At multiple timepoints up to Day 6
Time to alleviation of all influenza symptoms
Time frame: From treatment initiation up to Day 15
Duration of fever
Time frame: From treatment initiation up to Day 15
Time to cessation of viral shedding assessed by viral culture
Time frame: From treatment initiation up to Day 9
Change from baseline in viral titer
Time frame: Baseline to Day 9
Incidence of influenza-related complications
Time frame: Up to Day 15
Started Nov 2025 (actual). Primary completion is estimated for Jan 2026, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Joincare Pharmaceutical Group Industry Co., Ltd →